Actinium Pharmaceuticals (AMEX:ATNM) – With Pivotal Data Coming, Analyst Sees 145% Upside for Actinium

  • Cantor Fitzgerald began coverage on Actinium Pharmaceuticals Inc. ATNM with an overweight rating and a price target of $20, up almost 145%.
  • Actinium is a clinical-stage biopharmaceutical company currently developing oncology therapies.
  • This includes the lead program, IomabB, a targeted conditioning therapy delivered in preparation for bone marrow transplantation (BMT), adoptive cell therapy (ACT), and Actimab-B, combined with other therapeutic agents.
  • Related: Actinium’s targeted radiotherapy achieves 100% bone marrow transplantation.
  • The analyst believes that the SIERRA trial is the only randomized Phase 3 study that offers GMO as a treatment option for patients with active r/r acute myeloid leukemia (AML).
  • “We believe it is essential to focus on a ‘Goldilocks’ approach to finding a dose/regimen that balances safety and efficacy,” writes the analyst.
  • The potential expansion of Iomab-B may also go beyond the CD45 space, as conditioning remains an integral part of adoptive cell therapies.
  • “Actinium has already achieved proof of concept in some of these contexts. We believe this could significantly expand market opportunities and open the door to other partnerships.” Cantor writes.
  • Price Action: ATNM shares are up 9.59% at $8.23 when last checked on Thursday.

Sean N. Ayres